Gao Yimin, Yu Xiaoyan, Xue Binbin, Zhou Fei, Wang Xiaohong, Yang Darong, Liu Nianli, Xu Li, Fang Xiaohong, Zhu Haizhen
Department of Molecular Medicine, State Key Laboratory of Chemo/Biosensing and Chemometrics, Hunan University, Changsha, China.
Department of Molecular Medicine, State Key Laboratory of Chemo/Biosensing and Chemometrics, Hunan University, Changsha, China ; Research Center of Cancer Prevention & Treatment and Translational Medicine Research Center of Liver Cancer, Hunan Provincial Tumor Hospital (Affiliated Tumor Hospital of Xiangya Medical School of Central South University), Changsha, China.
PLoS One. 2014 Feb 28;9(2):e90333. doi: 10.1371/journal.pone.0090333. eCollection 2014.
NS2 protein is essential for hepatitis C virus (HCV) replication. NS2 protein was expressed and purified. Aptamers against NS2 protein were raised and antiviral effects of the aptamers were examined. The molecular mechanism through which the aptamers exert their anti-HCV activity was investigated. The data showed that aptamer NS2-3 inhibited HCV RNA replication in replicon cell line and infectious HCV cell culture system. NS2-3 and another aptamer NS2-2 were demonstrated to inhibit infectious virus production without cytotoxicity in vitro. They did not affect hepatitis B virus replication. Interferon beta (IFN-β) and interferon-stimulated genes (ISGs) were not induced by the aptamers in HCV-infected hepatocytes. Furthermore, our study showed that N-terminal region of NS2 protein is involved in the inhibition of HCV infection by NS2-2. I861T within NS2 is the major resistance mutation identified. Aptamer NS2-2 disrupts the interaction of NS2 with NS5A protein. The data suggest that NS2-2 aptamer against NS2 protein exerts its antiviral effects through binding to the N-terminal of NS2 and disrupting the interaction of NS2 with NS5A protein. NS2-specific aptamer is the first NS2 inhibitor and can be used to understand the mechanisms of virus replication and assembly. It may be served as attractive candidates for inclusion in the future HCV direct-acting antiviral combination therapies.
NS2蛋白对丙型肝炎病毒(HCV)复制至关重要。表达并纯化了NS2蛋白。制备了针对NS2蛋白的适配体,并检测了其抗病毒效果。研究了适配体发挥抗HCV活性的分子机制。数据表明,适配体NS2-3在复制子细胞系和感染性HCV细胞培养系统中抑制HCV RNA复制。NS2-3和另一种适配体NS2-2在体外被证明可抑制感染性病毒产生且无细胞毒性。它们不影响乙型肝炎病毒复制。在HCV感染的肝细胞中,适配体不会诱导干扰素β(IFN-β)和干扰素刺激基因(ISGs)。此外,我们的研究表明,NS2蛋白的N端区域参与了NS2-2对HCV感染的抑制作用。NS2内的I861T是鉴定出的主要耐药突变。适配体NS2-2破坏了NS2与NS5A蛋白的相互作用。数据表明,针对NS2蛋白的适配体NS2-2通过与NS2的N端结合并破坏NS2与NS5A蛋白的相互作用发挥其抗病毒作用。NS2特异性适配体是首个NS2抑制剂,可用于了解病毒复制和组装机制。它可能是未来HCV直接作用抗病毒联合疗法中有吸引力的候选药物。